715

(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE

Find entries where: 715

is present as a standalone ligand in 3 entries

Find related ligands:

Chemical Component Summary
Name	(2R)-4-OXO-4-[3-(TRIFLUOROMETHYL)-5,6-DIHYDRO[1,2,4]TRIAZOLO[4,3-A]PYRAZIN-7(8H)-YL]-1-(2,4,5-TRIFLUOROPHENYL)BUTAN-2-A MINE
Synonyms	Sitagliptin
Identifiers	(3R)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5H-[1,2,4]triazolo[3,4-c]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one
Formula	C₁₆ H₁₅ F₆ N₅ O
Molecular Weight	407.314
Type	NON-POLYMER
Isomeric SMILES	c1c(c(cc(c1F)F)F)C[C@H](CC(=O)N2CCn3c(nnc3C(F)(F)F)C2)N
InChI	InChI=1S/C16H15F6N5O/c17-10-6-12(19)11(18)4-8(10)3-9(23)5-14(28)26-1-2-27-13(7-26)24-25-15(27)16(20,21)22/h4,6,9H,1-3,5,7,23H2/t9-/m1/s1
InChIKey	MFFMDFFZMYYVKS-SECBINFHSA-N

Chemical Details
Formal Charge	0
Atom Count	43
Chiral Atom Count	1
Bond Count	45
Aromatic Bond Count	11

Drug Info: DrugBank

DrugBank ID	DB01261
Name	Sitagliptin
Groups	approved investigational
Description	Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improve control of blood sugar[FDA label,A2255]. Sitagliptin was granted FDA approval on October 16, 2006[L6061].
Synonyms	Sitagliptinum Sitagliptine Sitagliptin phosphate Sitagliptin Sitagliptina
Brand Names	Sitagliptin - Metformin Xelevia Steglujan Ristaben PMS-sitagliptin-metformin Ristfor Januvia Riva Sitagliptin Sitagliptin-metformin M-sitagliptin Janumet Apo-sitagliptin-metformin Reddy-sitagliptin and Metformin Hydrochloride Bio-sitagliptin Apo-sitagliptin/metformin XR PMS-sitagliptin Janumet XR Sandoz Sitagliptin Sitagliptin/metformin Hydrochloride Sun Sandoz Sitagliptin-metformin XR Sitagliptin Accord Sitagliptin/metformin Hydrochloride Accord Reddy-sitagliptin Sitagliptin Sun Zituvio Juvisync Apo-sitagliptin Nat-sitagliptin Sitagliptin Phosphate/Metformin Hydrochloride Sandoz Sitagliptin-metformin Tesavel Sitagliptin Velmetia Ach-sitagliptin Efficib
Indication	Sitagliptin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It is not used to treat type 1 diabetes or patients with a history of pancreatitis.[L41220] It is also used in combination with [metformin] [L41215] or [ertugliflozin].[L41225]
Categories	Agents causing angioedema Alimentary Tract and Metabolism Blood Glucose Lowering Agents Cytochrome P-450 CYP2C8 Substrates Cytochrome P-450 CYP3A Substrates Cytochrome P-450 CYP3A4 Substrates Cytochrome P-450 Substrates DPP-IV Inhibitors Drugs that are Mainly Renally Excreted Drugs Used in Diabetes Enzyme Inhibitors Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Hypoglycemia-Associated Agents Incretins OAT3/SLC22A8 Substrates Oral Hypoglycemics P-glycoprotein substrates Protease Inhibitors Triazoles
ATC-Code	A10BH51 A10BD24 A10BD07 A10BH01 A10BD12
CAS number	486460-32-6

Drug Targets

Name	Target Sequence	Pharmacological Action	Actions
Dipeptidyl peptidase 4	MKTPWKVLLGLLGAAALVTIITVPVVLLNKGTDDATADSRKTYTLTDYLK...	unknown	inhibitor
Cytochrome P450 3A4	MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...	unknown	substrate
Cytochrome P450 2C8	MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDI...	unknown	substrate
P-glycoprotein 1	MDLEGDRNGGAKKKNFFKLNNKSEKDKKEKKPTVSVFSMFRYSNWLDKLY...	unknown	substrate
Solute carrier family 22 member 8	MTFSEILDRVGSMGHFQFLHVAILGLPILNMANHNLLQIFTAATPVHHCR...	unknown	substrate

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682